Bonerge Announces the New 108 Person Clinical Trial: Exploring Skin and Organ Anti-Aging Innovations

In this clinical trial, Bonerge is examining the skin anti-aging effects of individual ingredients, as well as the combination of three ingredients to explore their synergistic effects on skin health and anti-aging. The trial is progressing as planned and is expected to conclude in March 2025. Bonerge hopes that this study will offer valuable evidence for the anti-aging market, potentially leading to the application of Senolytics in skin health and broader anti-aging treatments.

References:

• Chase M. Carver, et al. IL-23R is a senescence-linked circulating and tissue biomarker of aging. Nature Aging, Dec 2024.
• Researchers discover an aging and inflammation biomarker - Mayo Clinic News Network
• Matthew J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36 (2018).
• Wenjie Liu, et al. Urolithin A protects human dermal fibroblasts from UVA-induced photoaging through NRF2 activation and mitophagy. J Photochem Photobiol B. 2022 Jul.
• Brown, Lisa, et al. L-Ergothioneine and Its Protective Role in Cellular Health. Journal of Clinical Nutrition, vol 56.